Sugi Predict

Sugi Predict / Compounds / SCHEMBL16637206

SCHEMBL16637206

SCHEMBL16637206

CC(C)(C)OC(=O)N1CCN(c2ncnc3cc(Cl)c(C4CC4)cc23)CC1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.40
▸ KRAS P01116 8/20 0.39
▸ EIF2AK4 Q9P2K8 1/20 0.38
▸ KIT P10721 2/20 0.37
▸ JAK2 O60674 1/20 0.36
▸ SIRT2 Q8IXJ6 1/20 0.36
▸ SIRT1 Q96EB6 1/20 0.36
▸ SIRT3 Q9NTG7 1/20 0.36
▸ PDE10A Q9Y233 1/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ PRKDC P78527 1/20 0.35
▸ NR1H2 P55055 1/20 0.35
▸ NR1H3 Q13133 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29765688 1.00 MAP4K4 (0.40) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL21415547 0.91 MAP4K4 (0.41) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL16636620 0.88 MAP4K4 (0.41) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL16637201 0.86 KRAS (0.40) KRASPDE10AMAPK1PRKDC
SCHEMBL16636949 0.85 KRAS (0.40) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL16637209 0.84 MAP4K4 (0.40) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL22560917 0.84 MAP4K4 (0.40) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL17026606 0.84 MAP4K4 (0.40) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL29765684 0.84 MAP4K4 (0.40) MAP4K4KRASEIF2AK4KITJAK2
SCHEMBL29765753 0.84 MAP4K4 (0.40) MAP4K4KRASEIF2AK4KITJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20220242875-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2022-08-04 — — US disclosed
US-20210188869-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2021-06-24 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC 2016-06-16 — — US disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
WO-2016044772-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2016-03-24 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188869-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS MAP4K4 559/4885KRAS 1/4885EIF2AK4 2812/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS MAP4K4 568/4885KRAS 1/4885EIF2AK4 2589/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS MAP4K4 266/4885KRAS 1/4885EIF2AK4 2112/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS MAP4K4 266/4885KRAS 1/4885EIF2AK4 2112/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS MAP4K4 559/4885KRAS 1/4885EIF2AK4 2812/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS MAP4K4 559/4885KRAS 1/4885EIF2AK4 2812/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS MAP4K4 559/4885KRAS 1/4885EIF2AK4 2812/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS MAP4K4 559/4885KRAS 1/4885EIF2AK4 2812/4885
US-20220242875-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS MAP4K4 559/4885KRAS 1/4885EIF2AK4 2812/4885
US-20160166571-A1 COMBINATION THERAPIES FOR TREATMENT OF CANCER KRAS, TP53, HRAS MAP4K4 1204/4885KRAS 1/4885EIF2AK4 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.